AI assistant
ANTEOTECH LTD — Capital/Financing Update 2015
Aug 25, 2015
64304_rns_2015-08-25_465d2c31-a62a-45cf-b8f0-ac56dbb50625.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [276 x 85] intentionally omitted <==
DR GEOFF CUMMING DISCUSSES DIASOURCE ACQUISITION
For Immediate Release:
August 26, 2015
26 August 2015 - Anteo Diagnostics (ASX: ADO) ( Anteo ), is pleased to invite investors to listen to an audio interview with CEO, Dr Geoff Cumming, where he discusses the acquisition of DIAsource Immunoassays SA, an established global specialty diagnostics company based in Belgium.
In this audiocast, Dr Cumming covers:
-
An overview of the transaction, including an introduction to DIAsource, the markets it services, company fundamentals and recent performance
-
Anteo’s view on what makes the Anteo / DIAsource combination a good strategic fit
-
Financing and the anticipated timeframe to complete the acquisition
To listen to the audiocast, please copy the following link into your browser: http://www.brrmedia.com/event/140153
For further information, see our website (www.anteodx.com) or contact the persons outlined below.
| Company | Media and Investor Relations |
|---|---|
| Dr. Geoff Cumming, Chief Executive OfficerT: + 61 7 3219 0085Richard Martin, Chief Financial OfficerT: + 61 7 417 229 810 | Jane Lowe, IR DepartmentE: [email protected]T: + 61 411 117 774 |
About Anteo Diagnostics
Anteo Diagnostics Limited (ASX: ADO) is a global technology company and parent company of the Australian biotechnology company Anteo Technologies, that develops and commercialises products for the life sciences, in-vitro diagnostics, point of care, medical devices and bioseparations markets.
The Anteo group owns a patented nanoglue technology, which is used by healthcare customers as an addition to their existing tests, to consistently enable laboratory test results that can either be delivered faster, cheaper or with greater specificity and / or sensitivity than incumbent tests. This nanoglue technology, called Mix&Go for healthcare markets, is starting to gain traction within the Company’s target markets due to its ability to revolutionise the way scientists and assay developers work.
For more information, please visit www.anteodx.com
==> picture [588 x 138] intentionally omitted <==